| P50 | author | Erwan Bezard | Q38544252 |
| P2093 | author name string | Bioulac B | |
| | Gross CE | |
| | Imbert C | |
| | Deloire X | |
| P2860 | cites work | Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 |
| | Parkinsonism: onset, progression, and mortality | Q28259134 |
| | Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey | Q28270776 |
| | Core assessment program for intracerebral transplantations (CAPIT) | Q28295664 |
| | Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo | Q28306009 |
| | Chronic parkinsonism secondary to intravenous injection of meperidine analogues | Q28323857 |
| | Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism | Q28328337 |
| | Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system | Q34248307 |
| | Parkinson's disease: pathophysiology | Q36495393 |
| | MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease | Q37045190 |
| | A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q37343442 |
| | MPTP-induced parkinsonism | Q37911457 |
| | Neuronal basis of the parkinsonian resting tremor: a hypothesis and its implications for treatment | Q37945591 |
| | Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. | Q40611352 |
| | Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists | Q41154685 |
| | Striatal dopamine deficiency in Parkinson's disease: role of aging | Q41993839 |
| | Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions | Q42436109 |
| | Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. | Q43624609 |
| | Tremor in MPTP-induced parkinsonism | Q46130176 |
| | Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys | Q48316612 |
| | Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). | Q48321963 |
| | Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets | Q48347120 |
| | MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates | Q48446938 |
| | Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism | Q48460759 |
| | Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia | Q48468018 |
| | MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study | Q48486914 |
| | MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies | Q48593461 |
| | Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism | Q48626940 |
| | Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons | Q48937244 |
| | Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys | Q48951590 |
| | Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. | Q52210070 |
| | The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine to monkeys | Q57809499 |
| | Distribution of Catecholamines in the Ventral Mesencephalon of Human Brain, with Special Reference to Parkinson's Disease | Q64785695 |
| | Presymptomatic revelation of experimental parkinsonism. | Q67217591 |
| | Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP | Q69227608 |
| | Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin | Q69246322 |
| | Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q70951248 |
| | Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study | Q71149834 |
| | Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice | Q71860224 |
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 107-112 | |
| P577 | publication date | 1997-08-01 | |
| P1433 | published in | Brain Research | Q4955782 |
| P1476 | title | A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey | |
| P478 | volume | 766 | |